IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

Main Article Content

Alana Kennedy-Nasser *
Catherine Bollard
Helen Heslop
(*) Corresponding Author:
Alana Kennedy-Nasser | aakenned@txccc.org

Abstract

Latent EBV infection is associated with several malignancies, including EBV post-transplant lymphoproliferative disorders (LPD), Hodgkin and non-Hodgkin lymphomas, nasopharyngeal carcinoma and Burkitt lymphoma. The range of expression of latent EBV antigens varies in these tumors, which influences how susceptible the tumors are to immunotherapeutic approaches. Tumors expressing type III latency, such as in LPD, express the widest array of EBV antigens making them the most susceptible to immunotherapy. Treatment strategies for EBV-related tumors include restoring normal cellular immunity by adoptive immunotherapy with EBV-specific T cells and targeting the malignant B cells with monoclonal antibodies. We review the current immunotherapies and future studies aimed at targeting EBV antigen expression in these tumors.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Alana Kennedy-Nasser, Baylor College of Medicine

Assistant Professor of Pediatrics

Catherine Bollard, Baylor College of Medicine

Associate Professor of Pediatrics

Helen Heslop, Baylor College of Medicine

Professor of Medicine and PediatricsCenter for Cell and Gene Therapy